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In the last decade, miRNAs have received substantial attention as potential players of diabetes microvascular complications,
affecting the kidney, the retina, and the peripheral neurons. Compelling evidence indicates that abnormally expressed miRNAs
have pivotal roles in key pathogenic processes of microvascular complications, such as fibrosis, apoptosis, inflammation, and
angiogenesis. Moreover, clinical research into innovative both diagnostic and prognostic tools suggests circulating miRNAs as
possible novel noninvasive markers of diabetes microvascular complications. In this review, we summarize current knowledge
and understanding of the role of miRNAs in the injury to the microvascular bed in diabetes and discuss the potential of
miRNAs as clinical biomarkers of diabetes microvascular complications.
1. Introduction
Microvascular complications of diabetes (DMC) have a sig-
nificant impact on quality of life, morbidity, and mortality,
posing a huge burden on the health care system. Diabetic
nephropathy is a leading cause of end-stage renal disease
(ESRD) and augments the risk of cardiovascular diseases
(CVD). Diabetic retinopathy is the major cause of new
blindness in adults, and diabetic neuropathy contributes
to the development of foot ulcerations that are the pre-
dominant cause of nontraumatic lower limb amputation
among adults. Therefore, it is urgent to identify novel
targets for treatment and to discover innovative noninva-
sive biomarkers to improve risk prediction, early diagnosis,
and prognosis assessment.
MicroRNAs (miRNAs) have been recently implicated in
a growing number of pathophysiological conditions. More-
over, miRNAs are also present in biological fluids in a stable
form and have been proposed as noninvasive biomarkers.
Recently, a growing number of basic science studies have
demonstrated the key role of miRNAs in the pathogenesis
of DMC. In addition, clinical studies have provided prelimi-
nary evidence that miRNAs present in body fluids may be
exploited as biomarkers of DMC.
This review summarizes current knowledge on miRNAs
as both pathogenic mechanisms and biomarkers of DMC.
Furthermore, we will discuss potential future perspectives
and limits of this novel line of research.
2. MicroRNAs
MiRNAs are small (~22 nucleotides) noncoding RNA
sequences that inhibit gene expression of specific mRNA tar-
gets. MiRNAs are present in mammalians, plants, and some
viruses. Over 2500 mature miRNAs have been identified in
the human genome. Each of them regulates the expression
of multiple genes and single mRNAs are targeted by multiple
miRNAs; therefore, miRNAs are involved in a vast array of
pathophysiological processes [1].
2.1. MicroRNA Synthesis. The first step in miRNA synthesis
is the transcription of miRNA genes by RNA polymerase II
into large RNA precursors called pri-miRNAs, containing a
5′ cap and a poly-A tail [2]. As multiple miRNAs can be tran-
scribed from the same gene, pri-miRNAs can give rise to var-
ious mature miRNAs. Pri-miRNAs are processed in the
nucleus by the microprocessor complex, containing the
RNase III Drosha that cuts pri-miRNAs and releases stem-
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loop sequences of 60–70 nucleotides called pre-miRNAs [3].
The pre-miRNA is transferred from the nuclei to the cytosol
by the exportin-5 and Ran-GTP complex [4] In the cytosol,
the RNase III Dicer processes pre-miRNAs with formation
of duplex miRNAs (dsmiRNA), containing a guide and a pas-
senger strand. dsmiRNAs form an intermediate complex,
namedmiR-RISC (RNA-induced silencing complex), includ-
ing Dicer and both Argonaute (Ago) and TRBP proteins.
During this step, the passenger strand is removed and the
mature single-strand miRNA binds to Ago within a func-
tional RISC complex [5–8].
2.2. MicroRNA Function. Mature miRNAs act as a guide
allowing the RISC to recognize complementary sequences
at the 3′ untranslated region (3′ UTR) of their target mRNAs.
In most cases, the recognition occurs between the target
mRNA and a sequence of 2–8 bases of the miRNA [9]. The
predominant mechanism whereby miRNAs negatively con-
trol the expression of their targets is translational repression
and subsequent degradation of target mRNAs. Translational
repression is usually followed by mRNA degradation; how-
ever, this is not always the case and a repressed mRNA may
undergo translational reactivation. Degradation may occur
through different mechanisms. Ago proteins possess nuclease
activity and may directly degrade mRNAs. Alternatively, Ago
can function as a binding site for TNRC6-A/B/C proteins that
promote mRNA deadenylation. Following deadenylation,
mRNAs are rapidly degraded by 3′–5′ exonucleases [10].
3. Diabetes Microvascular Complications
3.1. Diabetic Retinopathy. In the developed countries, dia-
betic retinopathy (DR) is the leading cause of new blindness
in people aged 25–74 years. DR prevalence is strongly related
to both level of glycemic control and diabetes duration, and
intervention studies have convincingly demonstrated the
importance of hyperglycemia in the rate of both development
and progression of DR. There are two major DR stages: non-
proliferative (NPDR) and proliferative (PDR) retinopathy. In
NPDR, thickening of the basement membrane and pericytes/
endothelial cell loss result in increased vascular permeability
and development of microvascular abnormalities, such as
dilated vessels, capillary microaneurysms, shunts, and vascu-
lar occlusion. In the severe NPDR stage, vessel obliteration
deprives blood supply to areas of the retina that secrete fac-
tors to promote formation of new blood vessels. In PDR, both
leaking and breaking of immature and fragile new vessels can
cause vitreous hemorrhages, macula edema, fibrosis, retinal
detachment, and possibly sight loss. A low-grade inflamma-
tion is believed to contribute to both DR stages by amplifying
hyperglycemia-induced injury and partially mediating neo-
vascularization [11].
3.2. Diabetic Neuropathy. Diabetic neuropathies are the most
common complications of DM, affecting as many as 50%
of patients. Distal symmetric polyneuropathy (DSPN),
the most prevalent form of diabetic neuropathy, is a chronic,
symmetrical, length-dependent sensorimotor polyneuropa-
thy. DSPN develops after long-standing hyperglycemia and
can be stabilized by rigorous glycemic control. The complica-
tion is due to bothmetabolic derangement, directly damaging
the neurons, and injury of the small blood vessels supply-
ing the nerves. Axonal degeneration is the primary struc-
tural abnormality; however, demyelination resulting from
Schwann cell dysfunction also occurs. DSPN affects predomi-
nantly sensory neurons and symptoms vary according to the
class of sensory fibers involved. Early symptoms due to the
involvement of small fibers include pain and dysesthesias,
while anesthesia and poor balance develop at later stages [12].
3.3. Diabetic Nephropathy. Diabetic nephropathy (DN)
develops in almost a third of patients with diabetes and
accounts for 44% of incident ESRD in the United States.
Intervention studies in humans have demonstrated the key
pathogenic role of both hyperglycemia and hypertension in
DN both onset and progression. DN is characterized by
increased glomerular permeability to proteins and progres-
sive renal function decline. Injury and loss of glomerular
podocytes, thickening of the glomerular basement mem-
brane, mesangial expansion, and tubule-interstitial fibrosis
are the predominant structural abnormalities. Podocyte
dysfunction/damage is the major cause of albuminuria
development, while excessive extracellular matrix (ECM)
deposition leading to sclerosis is a key determinant of
progressive renal function loss [13, 14].
4. MicroRNAs as Cellular Mediator of DMC
Several studies have assessed the expression of miRNAs in
the tissues/cells from target organs of DMC, providing
evidence that miRNA expression profile is altered in both
human and experimental DMC (Table 1). However, these
studies have used nondiabetic controls as the comparator
group, and thus diabetes itself may account for part of the
observed changes.
miRNA expression profiling can facilitate the discovery
of miRNAs with a key role in DMC and also identify “molec-
ular miRNA signatures” associated with DMC. However, as
shown in Table 1, the reproducibility of the results obtained
in miRNA profiling studies is scarce even when only highly
differentially expressed and PCR-validated miRNAs are
considered. The presence of a myriad of potential con-
founders, including preanalytic and analytic variables, may
partially account for this. Regardless of the cause, only part of
miRNAs that were differentially expressed in profiling studies
was found to be important in subsequent dedicated analyses,
and most of the available data come from hypothesis-driven
studies, assessing selected candidate miRNAs.
In the next sections, we will review evidence for an
involvement of selected miRNAs in common pathophysio-
logical processes across DMC: angiogenesis, inflammation,
cell injury/apoptosis, and fibrosis. A list and description
of the most relevant miRNAs by complication are reported
in Tables 2–4.
4.1. MicroRNAs and Neovascularization in DMC. As
mentioned above, hypoxia-induced abnormal neovasculari-
zation is a characteristic feature of DR. The cytokine vascular
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endothelial growth factor (VEGF) plays a key role in this
process and anti-VEGF therapies have been proven effective
for the treatment of both diabetic macular edema and PDR.
Therefore, miRNAs that control VEGF signaling have been
extensively studied in the context of DR. Among them,
miR-126, miR-106, miR-15, and miR-200b directly target
VEGF, while miR-150, miR-184, and miR-155 indirectly
modulate VEGF either expression or signaling.
miR-126 is one of most studied miRNA in both diabetes
and diabetes complications because of its key role in endothe-
lial protection and angiogenesis. Levels of miR-126 are
reduced in the retina in experimental diabetes and other hyp-
oxic conditions [15], and there is evidence from studies in ani-
mal models of oxygen-induced retinopathy (OIR) of a causal
link between hypoxia-induced miR-126 downregulation and
the rise in retinal VEGF levels. For instance, intravitreous
injection of a plasmid vector expressing miR-126 reduced
both VEGF and neovascularization [16]. Of interest, a recent
study has shown that treatment with Niaspan, which nor-
malized retinal miR-126 levels, prevented overexpression of
VEGF as well as edema, hemorrhages, and apoptosis [17].
Moreover, a small case-control study also reported an asso-
ciation between a miR-126 polymorphism and both severe
NPDR and PDR in patients with type 2 diabetes [18]. There
is interdependence between hypoxia-induced factor 1α
(HIF1-α) and VEGF expression as silencing of HIF1-α
resulted in a significant reduction in VEGF protein levels
and vice versa in both in vitro and in vivo models of DR.
This interdependence is mediated by shared miRNAs, such
as miR-106, and overexpression of miR-106a significantly
Table 1: miRNA profiling studies in diabetic microvascular complications.
DMC Study design Source
Number of
ΔmiRNAs
Selected differentially expressed
miRNA
Ref
DR
STZ-DM rats versus controls
Retinas Δ86
↑ 31, 31∗, 34b-3p, 34c, 184,199a, 200a,
200b, 205, 223,
335-3p, 378∗, 488, 574-3p
↓ 20b, 499, 690
(17 PCR-validated miRNAs)
[22]
REC Δ120
↑ 15b, 19b, 21, 31, 132, 142-3p, 146a,
155, 339-5p,
342-3p, 450a
↓ 20b-5p, 29c, 181c, 136∗, 376c
(16 PCR-validated miRNAs)
db/db mice versus controls Retinas Δ6
↑ 21, 31, 132, 184, 379, 322
↓ 29b, 294∗, 376b, 690, 712
(>2-fold increase)
[41]
DM2 patients versus controls REC ↑ 60, ↓ 16
↑ 133 ↓ 10a, 10b, 15a
(4 PCR-validated miRNAs)
[21]
DSPN
STZ-DM mice versus controls DRG
↑ 74
↓ 68
↓ let-7i, 103, 16, 107, 130a, 30a, 29a,
138, 27a,
27b, let7g, 30b, let7f, 34a, 338-3p
↑ 191, 466-5p, 149∗, 341∗
(>1.5 fold-change)
[51]
STZ-DM mice versus controls
Spinal dorsal
horn
↑ 21
↓ 21
↑ 184-5p ↓190a-5p
(2 PCR-validated miRNAs)
[137]
DN
DN
FSGS
IgAN
MPGN
Controls
Human
glomeruli
DN: Δ18
FSGS: Δ12
IgAN: Δ2
MPGN: Δ17
versus controls
DN versus controls:
↑ 29a, 23a, 214, 21, 5585, 589, 150,
4286
↓ 486-3p, 486-5p, 1180, 4301, 30a-3p,
30c,
148a, 30a-5p, 3184, 423
DN versus FSGS: ↑ 24, 146a
DN versus MPGN:↑ 146a, 146b; ↓ 671
[37]
DM2 patients versus healthy
controls
Kidney
↑ 32
↓ 39
↑ 146a, 155
(2 PCR-validated miRNAs)
[28]
db/db mice versus controls Glomeruli ↓ 45
↓ 5 ↓ 92a, 92b, 93, 140, 191 [55]
HG versus NG
Podocytes ↓ 32
GEC ↓ 86
DMC: diabetic microvascular complications; DM: diabetes; DM2: type 2 diabetes; STZ-DM: streptozotocin-induced diabetes; DR: diabetic retinopathy; DN:
diabetic nephropathy; DSPN: diabetic peripheral symmetric polyneuropathy; HG: high glucose; NG: normal glucose; FSGS: focal segmental
glomerulosclerosis; MPGN: membranoproliferative glomerulonephritis; REC: retinal endothelial cells; GEC: glomerular endothelial cells; DRG: dorsal root
ganglia; Δ: differentially expressed miRNAs. ∗miRNA nomenclature.
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reduced the expression of both HIF1-α and VEGF and pre-
vented high glucose-induced increased permeability [19].
McArthur et al. showed a downregulation ofmiR-200b in
both experimental and human DR, and manipulation of
miR-200b levels confirmed that retinal VEGF expression
was under miR-200b control. Most importantly, they dem-
onstrated that a miR-200b mimic normalizes retinal VEGF
levels and reduces both neovascularization and enhanced
permeability in DM mice, providing evidence that miR-
200b is a key mediator of VEGF rise in DR and a potential
target for miRNA-based treatment [20]. Similarly, retinal
miR-15 was reduced in both experimental and human DR,
and overexpression of miR-15 reduced VEGF and amelio-
rated vascular leakage in DM animals. However, miR-15
has also anti-inflammatory properties and controls the
expression of acid sphingomyelinase, the central enzyme in
the sphingolipid metabolism; therefore, amelioration of
inflammation and lipotoxicity is a possible additional protec-
tive mechanism [21].
MicroRNA-150, miR-184, and miR-155 can indirectly
modulate VEGF signaling in DR. miR-150 affects VEGF by
inhibiting the expression of the type 2 VEGF receptor. This
Table 2: MicroRNAs Involved in Diabetic Retinopathy.
miRNA Source Model
miRNA
levels
Putative
targets
Pathogenic role Reference
126 Retinas STZ-DM rats, OIR mice ↓
VCAM-1
VEGF
↑ angiogenesis [15–17]
200b
Retinas STZ-DM rats and DM patients ↓ VEGF ↑ angiogenesis [20]
Vitreous
Patients with PDR, Akita-DR mice, STZ-
DM mice
↑
Oxr1
Snail1
Smad2
p300
↑ EMT [98–100]
15a
Retinas
RPE
cells
STZ-DM mice and STZ-DM rats, HRPE
cells
↓
VEGF-A
ASM
↑ angiogenesis, ↑ inflammation, ↑
lipotoxicity
[21]
150 Retinas
STZ-DM rats
HFD-DM mice (WT and miR-150−/−)
↓ VEGFR2 ↑ angiogenesis [22, 23]
184 Retinas OIR mice ↓ Frizzled-7 ↑ angiogenesis [24]
155 Retinas OIR mice ↑ SHIP1 ↑ angiogenesis [26]
146a
Retinas STZ-DM rats ↓
CARD10
IRAK1/2
TRAF6
↑ inflammation [22, 34]
Retinas STZ-DM rats and db/db mice ↓ Fibronectin ↑ fibrosis [30]
21 Retinas STZ-DM rats and db/db mice ↑ PPARα ↑ inflammation [22, 41]
195 Retinas STZ-DM rats ↑ SIRT1 ↑ apoptosis [62]
29b Retinas STZ-DM mice, STZ-DM rats ↓ Sp1 ↑ apoptosis [39, 52]
RPE: retinal pigment epithelial cells; STZ: streptozotocin; OIR: oxygen-induced retinopathy; DM: diabetes; PDR: proliferative diabetic retinopathy; HFD: high-
fat diet; WT: wild type; EMT: epithelial mesenchymal transition.
Table 3: MicroRNAs involved in diabetic neuropathy.
miRNA Source Model
miRNA
levels
Putative
targets
Pathogenic role Reference
146
Sciatic nerve
db/db
mice
↓
IRAK1/2
TRAF6
↑ inflammation, apoptosis [31, 32]
STZ-DM
rats
↑
IRAK1/2
TRAF6
Dysfunctional NF-кB-miR-146a negative
feedback loop
[27]
let-7i DRG neurons
STZ-DM
mice
↓ — ↓ neurotrophism regeneration [51]
29b DRG neurons
STZ-DM
rats
↓ Sp1 (?) ↑ apoptosis, ↓ regeneration [40]
29c
DRG neurons, sciatic nerve, and
foot pad tissues
db/db
mice
↑ PRKCI ↓ axonal growth [53]
341 DRG neurons
STZ-DM
mice
↑ — Unknown [51]
DRG: dorsal root ganglia; STZ: streptozotocin; DM: diabetic.
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Table 4: MicroRNA involved in diabetic nephropathy.
miRNAs Source Model
miRNA
levels
Putative targets Pathogenic role Reference
21
Glomeruli
Kidney
DM2 patients with albuminuria,
STZ-DM mice
↑
SMAD7, TGF-
βR2
PDCD4, Col4a1,
TIMP3
↓ fibrosis, ↓ podocyte damage [42]
Kidney
db/db mice
KK/Ay mice
↑ SMAD7 ↑ fibrosis, ↑ inflammation [44, 45]
Kidney OVE26 mice ↑ PTEN ↑ fibrosis [43]
Glomeruli db/db mice ↓ PTEN ↑ fibrosis [72]
25 Kidney
DM2 patients with DN
STZ-DM rats
STZ-DM mice and db/db mice
↓
PTEN
NOX4
CDC42
↑ oxidative stress, ↑ apoptosis, ↑ fibrosis,
↑ podocyte injury
[66–68]
26a Glomeruli
DM2 patients with DN
STZ-DM mice
↓ CTGF ↑ fibrosis [102]
27a
Glomeruli
Kidney
DM2 patients with DN
STZ-DM rats
↑ PPAR-γ ↑ podocyte damage, ↑ fibrosis [58, 101]
29a Glomeruli STZ-DM mice ↓ HDAC4 ↑ podocyte injury, ↑ fibrosis [54]
29b Kidney db/db mice ↓ SP1 ↑ fibrosis, ↑ inflammation [38]
29c Glomeruli db/db mice ↑ SPRY1 ↑ fibrosis, ↑ podocyte injury [59]
34a Glomeruli db/db mice ↑ GAS1 Glomerular hypertrophy [69]
93
Glomeruli
Kidney
db/db mice
DM patients with DN
↓ MSK2/VEGF ↑ VEGF, podocyte damage [55, 56]
130b
Glomeruli STZ-DM mice ↓ TGF-βR1 ↑ fibrosis [89]
Kidney DM2 patients and STZ-DM rats ↓ SNAIL ↑ EMT [105]
135a Kidney
DM patients with DN and
db/db mice
↑ TRPC1 ↑ fibrosis [103]
146a Kidney
DM2 patients with DN,
STZ-DM rats and DM2 rats
STZ-DM mice and db/db mice
↑ IRAK1, TRAF6 ↓ inflammation, ↓ fibrosis [28]
DM2 patients and ob/ob mice ↓
ERB-B4,
NOTCH-1
↑ podocyte injury [33]
155 Kidney
DM2 patients with DN,
STZ-DM rats and DM2 rats
STZ-DM mice
↑ SOCS1 ↓ inflammation, ↑ podocyte damage [28, 57]
192
Kidney
Patients with advanced DN
ApoE-KO DM mice
↓ ZEB1/2 ↑ EMT, ↑ fibrosis (tubule-interstitial) [91, 92]
Glomeruli
Kidney
STZ-DM mice and db/db mice
DM2 patients with early DN
↑ ZEB1/2 ↑ fibrosis (glomeruli)
[77, 78,
80]
195
Glomeruli
Kidney
STZ-DM mice (proteinuric) ↑ BCL2 ↑ podocyte damage/apoptosis [63]
Kidney Early DN mice ↓ BCL2 ↑ mesangial cell proliferation [64]
215
Glomeruli
Kidney
db/db mice ↑ CTNNBIP1 ↑ EMT [104]
Kidney ApoE-KO STZ mice ↓ ZEB2 ↑ EMT, ↑ fibrosis [87]
216a Glomeruli STZ-DM mice and db/db mice ↑ YBX1 ↑ fibrosis [81]
200b Kidney ApoE KO STZ mice ↓ ZEB1/2, FN ↑ EMT [93–95]
200b/c Glomeruli STZ-DM mice and db/db mice ↑ FOG2, ZEB1 Glomerular hypertrophy [73, 79]
377 Kidney STZ-DM mice and NOD mice ↑ PAK1, SOD2 ↑ fibrosis [90]
let-7a Kidney
DM2 patients with early DN
STZ-DM rats
↓
UHRF1
TGF-βR1
↑ fibrosis [88, 96]
let-7/7b
Glomeruli
Kidney
ApoE-KO STZ mice ↓
Col1a2, Col4a1
TGF-βR1
↑ fibrosis [85, 86]
STZ: streptozotocin; DM: diabetes; DN: diabetic nephropathy; KO: knockout; EMT: epithelial mesenchymal transition.
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miRNA is of relevance in DR as miR-150 is downregulated in
the diabetic retina [22] and miR-150 deletion exacerbated
retinal neovascularization in a model of high-fat diet-
induced diabetes [23], likely by further enhancing VEGF
signaling. miR-184 was downregulated in a model of
ischemia-induced retinal neovascularization [24]. Because
miR-184 controls the expression of frizzled-7, downregula-
tion of miR-184 can activate the canonical Wnt/frizzled-7
pathway that plays a central role in DR by enhancing neo-
vascularization through increased VEGF transcription [25].
Expression of miR-155 is induced by VEGF, and this is a
mechanism whereby VEGF enhances its downstream sig-
naling. In fact, miR-155 inhibits SHIP1, a counterregulator
of the VEGF-induced phosphoinositide 3-kinase (PI3K)/
Akt pathway. Moreover, studies in DR have shown that
retinal levels of miR-155 are enhanced in a model of OIR
and that treatment with a miR-155 antagomir can reduce
neovessel formation in a model of OIR via a SHIP1/PI3K/
Akt-dependent pathway [26].
Collectively, these data highlight the importance of miR-
NAs in modulating VEGF activity and thus retinal neovascu-
larization in DR and suggest that miRNAs may represent
novel targets for treatment. However, miRNAs affecting
VEGF in the diabetic retina have many other target genes,
increasing the likelihood of off-target effects.
4.2. MicroRNAs and Inflammation in DMC. A low-grade
chronic inflammation is believed to contribute to the patho-
genesis of DMC. Hyperglycemia and both hemodynamic and
oxidative stress are the main inducers of the inflammatory
response in DMC through activation of the transcription fac-
tor NF-κB. Monocyte chemoattractant protein 1 (MCP-1)
and other chemokines locally recruit monocyte/macrophages
that are predominantly of the M1 proinflammatory pheno-
type. Both resident cells and infiltrating macrophages release
inflammatory cytokines that contribute to cell damage and
promote inflammation-driven fibrosis. Among the multitude
of miRNAs implicated in the regulation of inflammatory
processes, miR-146, miR21, and miR-29 appear of particular
relevance in DMC.
miR-146a is a well-known modulator of both the innate
and adaptive immune response. In particular, miR-146
induction is a mechanism whereby NF-κB limits its proin-
flammatory activity. In fact, NF-κB activates miR-146a,
which in turn inhibits NF-κB by downregulating
interleukin-1 receptor-associated kinase 1/2 (IRAK1/2) and
TNF receptor-associated factor 6 (TRAF6). Therefore, miR-
146a is crucial to allow the timely resolution of ongoing
inflammatory processes.
miR-146a expression has been studied in the kidney, ret-
ina, and sciatic nerve from both patients with DMC and
experimental diabetic animals. Results are conflicting with
some studies reporting an increase [27–29] and other a
reduction in miR-146a expression [22, 30–33]. This likely
reflects variability in the compensatory anti-inflammatory
miR-146a response in various stages and models of DMC.
However, the observation that both NF-κB activity and
inflammatory cytokine levels were elevated even when miR-
146a was overexpressed suggests a state of relative miR-
146a deficiency with insufficient activation of the NF-кB-
miR-146a negative feedback loop [27]. Furthermore, a recent
study in podocytes has described a feed-forward loop result-
ing in a progressive reduction in miR-146 expression. Specif-
ically, MCP-1 upregulates the ribonuclease MCPIP1 that
antagonizes miR-146a. This reduces miR-146 inhibition
on its target gene ErbB4 and thus enhances signaling
through the TGF-β1-ErbB4 pathway, which increases
autocrine synthesis of MCP-1, further reducing miR-146a
levels [33] (Figure 1).
In keeping with these data, intervention studies have con-
sistently demonstrated an anti-inflammatory and protective
effect of miR-146a in DMC. In experimental DSPN, systemic
administration of a miR-146a mimic improved both func-
tional and structural alterations of DSPN and induced a shift
from M1 to M2 macrophages [31, 32]. In experimental DR,
intravitreal injection of miR-146a ameliorated both micro-
vascular leakage and retinal functional defects and reduced
expression of intercellular adhesion molecule 1 (ICAM-1), a
NF-κB downstream gene [34]. In experimental DN, deletion
of miR-146a exacerbated proteinuria, fibrosis, and macro-
phage infiltration and induced an M2 to M1 macrophage
shift with inflammasome activation [29], while treatment
with erlotinib, a pan-ErbB kinase inhibitor, ameliorates
podocyte injury and albuminuria by preventing ErbB4
induction secondary to miR-146 downregulation [33].
There is relatively little information on miR-146a in
human DMC; however, a miR-146a polymorphism was asso-
ciated with both DN and DSPN [35, 36]. Moreover, in a
recent study comparing miRNA expression in human glo-
meruli from patients with various kidney diseases, the
expression levels of miR-146a and miR-30a, used in combi-
nation, could effectively distinguish DN from all other renal
conditions except IgA nephropathy [37], suggesting a poten-
tial relevance of miR-146a in the differential diagnosis of
renal diseases.
MicroRNA-29b is of relevance in the context of inflam-
mation because it can reduce NF-κB activity by targeting
Sp-1, a transcriptional factor playing a key role in the activa-
tion of the NF-κB pathway. The expression of miR-29b was
reduced in experimental DN, and treatments increasing
miR-29b levels reduced microalbuminuria, renal fibrosis,
and Sp-1/NF-κB-driven inflammation in diabetic animals
[38]. However, this benefit cannot be entirely ascribed to
miR-29b anti-inflammatory properties because Sp-1 can also
modulate TGF-β1 signaling/apoptosis. miR-29 is also down-
regulated in both DR and DSPN [39, 40], but there are no
data on a potential anti-inflammatory role of miR-29b in
these complications.
miR-21 is overexpressed in both DR and DN [22, 41–45]
and contributes to the pathogenesis of DR by enhancing
inflammation. Indeed, intervention studies have shown that
both miR-21 deletion and intravitreal injection of a miR-21
inhibitor ameliorated retinal leakage and inflammation at
least in part via upregulation of peroxisome proliferator-
activated receptor-α (PPAR-α) [22, 41], which is a miR-21
target and inhibits NF-κB by upregulating IκB-α. However,
PPAR-α has also other beneficial effects particularly on
metabolism that may explain its protective effect. There are
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no data on miR-21 expression in DSPN; however, miR-21 is
upregulated in models of peripheral neuronal injury [46],
and a recent study has described an unforeseen link between
miR-21 and inflammation. Injured dorsal root ganglia
(DRG) neurons release exosomes enriched in miR-21 that
are phagocytized by macrophages in which miR-21 promotes
a proinflammatory phenotype. Therefore, both upregulation
and release of miR-21 appears to play a key role in sensory
neuron-macrophage communication after damage to the
peripheral nerve [47]. Likely future studies will explore if a
similar mechanism is at play in DMC.
4.3. MicroRNA and Cell Injury/Apoptosis in DMC. Cell dam-
age eventually leading to apoptosis is a characteristic feature
of DMC. Moreover, both podocytes and neurons are termi-
nally differentiated cells; therefore, their damage has irrevers-
ible effects. Abnormally expressed miRNAs have been
involved in diabetes-induced cell injury and herein we will
focus in particular on miRNAs affecting neurons, podocytes,
mesangial cells (MCs), and proximal tubular epithelial cells
(TECs), as the role of miRNAs in microvascular endothelial
cells has been recently reviewed elsewhere [48–50].
Several abnormally expressed miRNAs have been impli-
cated in the pathogenesis of DSPN because they can enhance
apoptosis and/or interfere with neuronal regenerative pro-
cesses. let-7i was the most downregulated miRNA in a profil-
ing study on diabetic DRG. Moreover, intranasal injection
with a let-7i mimic improved experimental DSPN, and let-
7i enhanced both growth and branching of cultured neurons
[51], indicating a protective neurotrophic activity. Similarly,
miR-29b expression was reduced in diabetic DRG and inter-
ventions normalizing its levels diminished neuron apoptosis
and increased regenerative processes [40]. miR-29b also
affects the neuronal component of the diabetic retina. Specif-
ically, miR-29b prevents apoptosis of cultured retinal Müller
cells by inhibiting its target gene Sp-1, and thus the downreg-
ulation of miR-29b observed in the diabetic retina may favor
apoptosis [52]. On the contrary, another member of the miR-
29 family miR-29c is overexpressed in both DRG neurons
and sciatic nerve of diabetic mice and negatively regulates
axonal growth by suppressing protein kinase C-iota [53].
Recent studies have explored the role of miRNAs in
podocyte damage in diabetes. Nephrin, a major component
of the junction connecting foot processes of adjacent podo-
cytes, is crucial to prevent protein leaking, and miR-29,
miR-155, and miR-93 have been causally linked to nephrin
loss in diabetes. Lin et al. have shown that miR-29a was
downregulated in the glomeruli from diabetic mice and that
miR-29a overexpression attenuated nephrin downregulation,
podocyte apoptosis, and proteinuria. The beneficial effect of
miR-29a was due to inhibition of histone deacetylase
(HDAC4) that causes nephrin deacetylation, ubiquitination,
and loss. Not only was HDAC4 a miR-29a target, but also
lowered miR-29a expression via an epigenetic mechanism
[54], fueling a deleterious vicious cycle. Similarly, a reduction
in miR-93 expression was found in both diabetic glomeruli
and podocytes exposed to high glucose [55]. Moreover, dia-
betic mice with inducible overexpression of miR-93 exclu-
sively in podocytes exhibited significant improvements of
albuminuria, nephrin downregulation, foot process efface-
ment, and podocyte loss. miR-93 has an important role in
chromatin reorganization by modulating its target MSK2, a
histone kinase, and its substrate H3S10, and miR-93 consti-
tutive expression is required to maintain podocyte health.
Because miR-93 expression is reduced by hyperglycemia,
miR-93 is a critical link between altered metabolism and
miR 146NF-휅B
Inflammatory
genes
TGF-훽1
ErbB4
↑ notch-1
Fn
IRAK1/2
TRAF6
MCP 1
(a)
↑ NF-휅B
↑ inflammatory
genes
↑ MCP 1 ↑ MCPIP1
↑ TGF-훽1
↑ Notch 1
ErbB4
↑ Fn
↑ STAT3
Podocyte
damageInflammation
Fibrosis
Diabetes
IRAK1/2
TRAF6 ?
miR 146
absolute/relative
deficiency
(b)
Figure 1: Role of miR-146a in diabetic microvascular complications. (a) In normoglycemic conditions, miR-146 is induced by NF-κB, and it
inhibits NF-κB by suppressing its target genes interleukin-1 receptor-associated kinase 1/2 (IRAK1/2) and TNF receptor-associated factor 6
(TRAF6). Moreover, miR-146 represses expression of fibronectin (Fn) in retinal cells and ErbB4/Notch1 in podocytes. (b) In the presence of
diabetes, there is an absolute/relative miR-146 deficiency leading to insufficient inhibition (light blue lines) of IRAK1/2/TRAF6 (enhancing
inflammation), Fn expression (favoring fibrosis), and TGF-β1/ErbB4/Notch1 signaling (leading to podocyte damage). Enhanced signaling
through the TGF-β1-ErbB4 pathway increases autocrine synthesis of MCP-1, further reducing miR-146a levels via MCPIP1 in a feed-
forward loop. Grey boxes: miR-146 target genes; dotted lines: inhibition; continuous line: activation/induction.
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podocyte epigenetic alterations [56]. Finally, miR-155 was
overexpressed in both human and experimental DN [28,
57], and its deletion enhanced expression of nephrin, acety-
lated nephrin, and Wilms tumor 1 (WT-1), a marker of
podocyte differentiation, through upregulation of suppressor
of cytokine signaling 1 (SOCS1) that inhibits the Janus kinase
2 (JAK2)/signal transducer and activator of transcription 1
(STAT1) pathway [57], indicating a deleterious effect of
diabetes-induced glomerular miR-155 overexpression.
Besides nephrin downregulation, alterations of the podo-
cyte cytoskeleton have also been implicated in proteinuria,
foot process effacement, and podocyte loss. miRNAs abnor-
mally expressed in response to hyperglycemia/TGF-β1
appear to contribute. In podocytes, high glucose induces
miR-27a that activates β-catenin signaling by negatively tar-
geting PPAR-γ. This leads to increased podocyte mesenchy-
mal transition, disrupted podocyte architectural integrity,
downregulated nephrin, and increased podocyte apoptosis.
The in vivo relevance was proven in experimental DN and
miR-27a upregulation confirmed in human diabetic kidney
biopsies [58]. In cultured podocytes exposed to high glucose,
miR-29c suppresses its target gene Spry1, resulting in both
abnormal activation of Rho kinase, a key regulator of the
podocyte cytoskeleton, and apoptosis. This is in agreement
with in vivo studies showing miR-29c upregulation in the
glomeruli from db/db mice and amelioration of DN in
miR-29c knockdown mice [59]. Of interest, linagliptin
inhibits the enzyme dipeptidyl peptidase-4 (DPP-4) that
degrades miR-29, and the beneficial effect of linagliptin treat-
ment in experimental DN may be partially ascribed to a
reduction in miR-29 levels [60]. Finally,miR-135a is induced
by TGF-β1 in cultured podocytes and causes severe podocyte
injury and disarray of the podocyte cytoskeleton by downreg-
ulating transient receptor potential channel 1 (TRPC1) [61].
Several miRNAs modulate apoptosis in renal and/or ret-
inal cells predominantly by affecting TGF-β1 signaling. The
expression of miR-21 is enhanced in both human and exper-
imental DN [42–45], and recent work by Lai JY et al. suggests
that both hyperglycemia and TGF-β1 induce miR-21 that in
turn functions as a feedback inhibitor of TGF-β-induced
podocyte apoptosis. Consistent with this notion, miR-21
deletion worsened albuminuria, podocyte loss, and renal
injury in both diabetic and TGF-β1 transgenic mice. In vitro
studies in podocytes have clarified that the beneficial effect of
miR-21 is due to downregulation of proapoptotic target
genes (Smad7, TGFR2, and Pdcd4) [42]. Sirtuins (SIRTs)
are potent inhibitors of apoptosis and both miR-195 and
miR-20b have been shown to affect apoptosis in DMC by
suppressing members of the SIRT family. Specifically, miR-
195 was overexpressed in both the retina and the kidney of
diabetic animals, and both miR-195 and miR-20 mediated
high-glucose-induced apoptosis of renal cells by suppressing
SIRT1 and SIRT7, respectively [62–65].miR-25 is downregu-
lated in both human and experimental DN, and this defi-
ciency has detrimental effects on both MCs and TECs as
miR-25 prevents TEC apoptosis by modulating the phospha-
tase and tensin homolog (PTEN)/Akt pathway and reduces
oxidative stress in MCs by targeting NADPH oxidase 4
(Nox4). Consistent with a protective role of miR-25, systemic
administration of a miR-25 mimic ameliorated DN [66–68].
Several other miRNAs affect apoptosis; however, given their
predominant effect on fibrotic processes, they will be
described in the next session.
In the diabetic kidney, MCs undergo proliferation and
then hypertrophy, a change in phenotype that preludes to
enhanced expression of ECM components. Expression of
miR-34 is enhanced in DN and miR-34 induces MC prolifer-
ation by targeting GAS1 [69]. This is in contrast with the
effect of miR-34 in retinal cells, where this miRNA reduces
cell proliferation by inhibiting LGR4 [70]. MC hypertrophy
is induced by miR-21 through inhibition of its target gene
PTEN and activation of the Akt/target of rapamycin complex
1 (TORC1) pathway. This together with the profibrotic
effects of miR-21 in MCs may explain reports of amelioration
of DN in diabetic miR-21 knockout mice despite the protec-
tive antiapoptotic effect of miR-21 on podocytes [43, 71, 72].
Another miRNA implicated in MC hypertrophy is miR-
200b/c, which is overexpressed in experimental DN. Specifi-
cally, TGF-β1 induces expression of miR-200b/c that causes
downregulation of the PI3K inhibitor FOG2, leading to MC
hypertrophy through the PI3K/Akt pathway [73].
Collectively, these data underscore the relevance of
miRNA in cell health and the contribution of miRNAs in
the pathogenesis of the cellular injury induced by diabetes.
4.4. MicroRNAs and Fibrosis in DMC. Excessive deposition of
ECM components, mainly collagen and fibronectin, leading
to sclerosis, occurs in all DMC, but it is a predominant fea-
ture of DN, and thus most of the studies assessing the role
of miRNAs on fibrosis were performed in this complication.
The prosclerotic cytokine TGF-β1, which is released by
resident cells in response to diabetes-related insults, acts
locally via autocrine/paracrine mechanisms and is a key
mediator of fibrotic processes in both the glomeruli and the
tubule interstitium. Several studies have thus investigated
the complex interplay between miRNAs and TGF-β1 on
renal fibrosis (Figure 2). TGF-β1 induces the expression of
profibrotic miR-216 and miR-377, while it represses antifi-
brotic miR-29 and let-7. Data on the effect of TGF-β1 on
miR-192 are more conflicting with contrasting results
in vitro in MCs and TECs and also in vivo where miR-192
was found both upregulated and downregulated in experi-
mental DN. This may be due to differences in animal models,
disease stages, and/or in vitro experimental conditions. In
MCs, miR-192 is induced initially through Smad3 signaling
and then through a long-lasting epigenetic mechanism
involving Ets1 and histone H3 acetylation by Akt-activated
p300, and this is consistent with findings in the glomeruli
from db/db mice [74]. On the contrary, in TECs, TGF-β1
represses miR-192 transcription by decreasing the binding
of HNF to the miR-192 gene [75]. HNF expression is
restricted to the tubules and this may partially explain the cell
specificity of miR-192 expression [76].
The collagen gene has E-box regulatory elements placed
in its far upstream region. In MCs exposed to TGF-β1 and
in glomeruli from diabetic mice, upregulation of miR-192
and miR-200b/c increases Col1a2 and Col4a1 expression by
inhibiting the E-box repressors Zeb1 and Zeb2 [77–79].
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Consistent with this, a negative correlation between miR-192
and both Zeb1 and Zeb2 expression has been reported in
patients with type 2 diabetes [80]. Moreover, diabetic mice
either knockout for miR-192 or treated with miR-192 inhib-
itors had a less severe renal phenotype with amelioration of
glomerular hypertrophy, fibrosis, and proteinuria [77, 78,
80]. In MCs, TGF-β1 also promotes expression of Col1a2
via upregulation ofmiR-216a. This effect is mediated by post-
transcriptional upregulation of Tsc22 by Ybx1, which is a
RNA-binding protein targeted by miR-216a. The interaction
of Tsc22 with the transcription factor E3 increases Col1a2
expression and, in keeping with this, a significant increase
of miR-216 and Tsc22 with parallel Ybx1 downregulation
was observed in the glomeruli of diabetic mice [81]. Members
of the miR-29 and let-7a, b, c families suppress the transcrip-
tion of collagen and have an antifibrotic effect. TGF-β1 coun-
teracts this antifibrotic effect by downregulating both miR-29
and miR-7a, b, c [82–89]. Consistent with this, miR-29b
overexpression ameliorates DN [38, 82]. Moreover, in a
model of advanced DN, an angiotensin receptor blocker that
enhanced miR-29 expression reduced both ECM deposition
and renal fibrosis [84]. In MCs, TGF-β1 can also affect fibro-
nectin expression through miR-377. Specifically, TGF-β1
enhances expression of miR-377 that increases fibronectin
levels by both inhibiting PAK1 and increasing oxidative
stress through suppression of superoxide dismutase (SOD)-
1/2 genes [90].
As mentioned above, the interplay between miR-192 and
TGF-β1 differs in TECs. In these cells, TGF-β1 induces a
downregulation ofmiR-200,miR-192, andmiR-215. As these
miRNAs inhibit Zeb1 and Zeb2, this results in E-cadherin
downregulation. E-cadherin is not only an epithelial marker,
but is also involved in cell-to-cell adhesion, and E-cadherin
dysregulation induces phenotypic changes contributing to
epithelial mesenchymal transition (EMT) and thus to renal
fibrosis [91–95].
A number of miRNAs affect fibrosis by enhancing TGF-
β1 signaling. For instance, TGF-β1 downregulates let-7a, b, c
and miR-130 that are known to suppress expression of the
TGF-β1 receptor of type 1 [85–89, 96]. The downregulation
TGF-훽1
TGF-훽R1
Smad3
↑ miR-192 ↑ miR-200bc
↓ ZEB1/2
↑ E-box
↑ collagen
chains
↑ TGF-훽1
↓ miR-192
↑ miR-216
↑ miR-377
↓ PAK
SOD1/2
↑ Fibronectin
↓ miR-200↓ miR-215
↑ ZEB1/2 ↓ E-cadherin ↑ EMT
↓ Ybx1
↑Tsc22
↓ mir-92b
↑ miR-27a
↓ PPAR-훾
↓ miR-93
↑ CTGF
↓ miR-26a
↑ miR-35a ↓ TRPC1
↓ miR-130b ↑ Snail
↓ miR-130
↓ Let-7a, b, c
↑ miR-21
↓ Smad7
↓ miR-29
↑ VEGF
↑ miR-215
↓ CTNNBIP1
↑ MMT
Figure 2: MicroRNAs involved in renal fibrosis in diabetes. MicroRNAs (miRNAs) implicated in glomerular (cream-coloured area) and
tubule-interstitial (light purple-coloured area) fibrosis in diabetes. The image shows miRNAs in red boxes that are modulated by TGF-β1
and directly control collagen/fibronectin expression, miRNAs in bronze boxes that enhance TGF-β1 signaling, and miRNAs in purple
boxes that affect fibrosis independently of TGF-β1. Target genes are shown in orange boxes. Grey lines indicate induction, while red lines
indicate suppression of miRNA expression. EMT: epithelial mesenchymal transition; MMT: mesangial cell to myofibroblast transition;
CTNNBIP1: catenin beta interacting protein 1; TGF-β1: transforming growth factor-β1; TGFB-R1: transforming growth factor type 1
receptor; VEGF: vascular endothelial growth factor; CTGF: connective tissue growth factor.
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of miR-92b enhances Smad3 expression, while TGF-β1-
inducedmiR-21 represses the expression of inhibitory Smad7
[43–45, 97]. Recently, Kato et al. have described a positive
circuit whereby miR-200b/c enhances TGF-β1 expression in
MCs. TGF-β1-induced miR-192 represses Zeb1/2, leading
to TGF-β1 and miR-200b/c expression. In turn, miR-200b/
c by inhibiting Zeb1/2 further enhances the effect of miR-
192 on TGF-β1 [79]. Of interest, miR-200b/c has also been
implicated in the fibrotic processes occurring in the diabetic
retina. Specifically, miR-200b is increased in human PDR
[98] and experimental DR [99] and promotes EMT both
in vitro and in vivo [100]. Finally, diabetes-induced miR-
27a overexpression promoted fibrosis in both TECs and dia-
betic rats by targeting PPAR-γ and indirectly enhancing
TGF-β/Smad3 signaling [101].
There are also miRNAs that can affect fibrosis in a TGF-
β1-independent manner. In podocytes, downregulation of
miR-93 and miR-26 enhances both fibronectin and collagen
expression by reducing the inhibitory effects of miR-93 and
miR-26 on VEGF and connective tissue growth factor
(CTGF), respectively [102]. In MCs, miR-135a induces syn-
thesis of ECM components by inhibiting its target gene
TRPC1, and miR-135a deletion restores levels of TRPC1
and reduces production of both fibronectin and collagen type
I in experimental DN [103]. miR-215 contributes to renal
fibrosis in DN by suppressing its target gene catenin-β inter-
acting protein 1 and thus favoring the transition of MCs to
myofibroblasts [104]. miR-130b is downregulated in DN
and miR-130 overexpression improves tubulointerstitial
fibrosis via repression of Snail-induced EMT [105]. Deletion
ofmiR-146 worsens kidney injury at least in part by targeting
the ErbB4 and Notch-1 pathway [33]. In addition, miR-146
can directly control fibronectin expression in retinal cells
and in vivo a miR-146 mimic normalized fibronectin levels
in the retina of diabetic mice [30].
Taken together, these studies prove the crucial role of
miRNAs in regulating ECM production and have given us a
deeper understanding of the complex mechanisms involved
in diabetes-induced fibrotic processes.
5. Circulating miRNAs
miRNAs are also present in biological fluids, such as serum,
plasma, saliva, urine, milk, and humor vitreous. Although
their role is not completely understood, they are likely
involved in cell-to-cell communication. In fact, after release
by parental cells, circulating miRNAs can translocate into
recipient cells in which they regulate gene expression.
miRNAs are very stable in biological fluids as they are
either enclosed in microparticles or assembled into com-
plexes that protect them from endogenous RNases. Cells
can actively secrete miRNAs packed into exosomes, which
are small vesicles released by cells through a tightly regulated
active process [106]. Alternatively, miRNAs can be passively
released in either apoptotic bodies or microvesicles (MV) by
cells exposed to insults [107, 108].
miRNAs are increasingly recognized as a promising bio-
marker, given the ease with which they can be isolated and
their structural stability under different conditions of sample
processing and isolation. Data showing that circulating
miRNA profiling can be disease-specific representing a
molecular signature of the disease support the hypothesis
that miRNAs can be valuable clinical biomarkers [109].
Several studies have investigated whether changes of
miRNA levels in body fluids are associated with DN and
DR, while no study on circulating miRNAs in DSPN is yet
available despite evidence of alterations of intracellular miR-
NAs in DSPN. Clinical miRNA studies differ substantially in
study design, patient sample size, type of diabetes, and body
fluid analyzed (Table 5). Most studies performed miRNA
profiling and validated highly differentially expressed miR-
NAs, while studies on candidate miRNAs focused on miR-
NAs known to be altered in relevant tissues.
5.1. Circulating MicroRNA and DMC. Based upon profiling
results, Wang et al. validated 13 miRNAs and confirmed
enhanced serum levels of miR-661, miR-571, miR-770-5p,
miR-892b, and miR-1303 in subjects with type 2 diabetes
and DMC. Among them, miR-1303, a miRNA involved in
autophagy, is of particular relevance as high miR-1303 levels
conferred an over threefold increased risk of DMC indepen-
dently of body mass index and blood pressure [110]. Sebas-
tiani et al. identified miR-31 as an upregulated miRNA in
patients with DMC, and this miRNA is likely involved in
angiogenesis and vascular permeability based on its predicted
target genes (E-selectin, integrin-α5, and nitric oxide syn-
thase 1) [111].
5.2. Circulating MicroRNAs and Diabetic Retinopathy. Three
miRNA profiling studies have been performed on serum
samples from patients with and without DR, allowing the
identification of potential biomarkers of DR.
In a nested case-control study on two prospective cohorts
of patients with type 1 diabetes from the DIRECT-1 trial
(PROTECT-1 and PREVENT-1), Zampetaki et al. profiled
29 miRNAs and validated relevant miRNAs. They found that
two miRNAs, miR-27b and miR-320a, were associated with
the incidence and the progression of DR. Furthermore, pro-
teomic analysis performed in endothelial cells showed that
the antiangiogenic protein thrombospondin-1 was a target
of both [112].
We have recently performed a miRNA profiling in
pooled serum samples from type 1 diabetic patients with
and without diabetic complications from the nested case-
control study of the EURODIAB PCS. Among the 25 differ-
entially expressed miRNAs, miR-126 was validated. miR-
126 levels were lower in cases than in controls and inversely
associated with all complications as well as with each compli-
cation examined separately. After adjustment for age, sex,
A1C, and diabetes duration, a 25% risk reduction was still
observed for PDR [113]. A significant decrease in serum
miR-126 levels was also reported by another study performed
in patients with type 2 diabetes and PDR [114]. Therefore,
several studies on both intra- and extracellular miR-126 indi-
cate a key role of this miRNA in PDR.
Qing et al. performed a differential miRNA profiling of
serum samples from subjects with DR and identified 3 miR-
NAs (miR-21, miR-181c, and miR-1179) significantly
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increased in patients with PDR [115]. A rise in plasma miR-
21 levels in patients with type 2 diabetes and DR has also
been confirmed by another study [116], and these data are
in line with studies showing miR-21 upregulation in experi-
mental DR. Similarly, plasma miR-93 levels were greater in
patients with type 2 diabetes and DR compared to those in
patients without DR [117].
5.3. Circulating MicroRNAs and Diabetic Nephropathy.
Pezzolesi et al. performed a prospective study on circulating
miRNAs in DN. Specifically, they assessed if the circulating
levels of 5 miRNAs, which are under the control of TGF-β,
predicted the development of ESRD during follow-up in
patients with type 1 diabetes and proteinuria but normal
renal function at baseline. They found that let-7c-5p and
miR-29a-3p were associated with an over 50% reduction of
the risk of rapid progression to ESRD, while let-7b-5p and
miR-21-5p were associated with a 2.5-fold increase in ESRD
risk independently of HbA1c and other confounders [118].
This finding is of particular relevance given the lack of clini-
cal biomarkers to predict ESRD and supports the hypothesis
that measurement of miRNA circulating levels may be of
relevance in clinical practice to identify subset of patients at
high risk.
Recently, Zhou et al. performed a miRNA microarray
assay in patients with type 2 diabetes and found that let-7a
was differentially expressed in patients with DN as also
confirmed by PCR. In addition, they discovered that the
rs1143770 variant of the let-7a-2 gene was associated with
an increased risk for DN [119].
Other studies focused on selected miRNAs and reported
significant changes in the circulating levels of miR-217, 21,
29a, 192, 130, and 126 in type 2 diabetes patients with and
without albuminuria [120–123]. However, given the cross-
sectional design of these studies, it is unknown whether these
miRNAs can help predicting either the development or the
progression of DN. Moreover, levels of miRNAs were often
correlated with HbA1c, and it is thus unclear whether these
changes in miRNA levels were specific of DN or simply mir-
rored worse metabolic control in patients with albuminuria.
5.4. Urinary miRNAs in DN. Urine is another body fluid that
has been used to identify miRNA biomarkers in DN. Two
studies on the urinary sediment from patients with chronic
kidney diseases showed that miR-15 and miR-192 levels were
lower in patients with DN than those in subjects with other
kidney diseases [124, 125], suggesting that circulating
miRNA may be of practical value in the differential diagnosis
of renal diseases.
Other groups have measured free miRNAs into urine. A
recent study found that urinary miR-2861, miR-1915-3p,
and miR-4532 levels were enhanced in patients with DN
and correlated with both renal function and tubulointerstitial
injury [126]. Argyropoulos et al. performed a miRNA profil-
ing in patients with type 1 diabetes and worsening stages of
albuminuria and found 27 differentially expressed urinary
miRNAs [127]. Importantly, the same group also carried
out a prospective study assessing the expression of 723 uri-
nary miRNAs in patients with type 1 diabetes who were
normoalbuminuric at baseline. Eighteen miRNAs were
found associated with microalbuminuria development, and
9 of them were used to define a miRNA signature for micro-
albuminuria [128].
More recently, several studies have measured/profiled
miRNAs enclosed in urinary exosomes/MVs. In type 1 diabe-
tes, we reported that urinary exosomes from patients with
microalbuminuria were enriched in miR-130a and miR-
145, while their content in miR-155 and miR-424 was
reduced. Of interest, exosomes either released by MCs
exposed to high glucose or isolated from the urine of animals
with DN were also enriched in miR-145 [129]. Other studies
on urinary exosomes/MVs were performed in patients with
type 2 diabetes. Delić et al. identified 16 differentially
expressed miRNAs in urinary exosomes from patients with
DN and confirmed that exosomal miR-320 and miR-6068
content was greater in patients with DN [130]. Another study
showed increased levels of miR-133b, miR-342, and miR-30a
in patients with DN [131]. Finally, a study performed on uri-
nary MVs from patients with type 2 diabetes and different
degrees of albuminuria revealed that miR-192, miR-194,
and miR-215 levels were specifically increased in patients
with microalbuminuria and that there was a correlation
between miR-192 and TGF-β1 levels as expected based on
their close relationship in renal tissue [132].
6. Future Perspective and Limits of This
Line of Research
In the last decade, much progress has been made in our
understanding of miRNA role in the pathogenesis of DMC.
Today, we know that several miRNAs are deregulated and
play a major pathogenic role in DMC. Moreover, vascular
complications of diabetes share, at least in part, insults and
underlying pathogenic mechanisms, and some miRNAs have
been implicated in multiple diabetes complications
(Figure 3). The best example is miR-146 that is involved in
all DMC and also in the pathogenesis of atherosclerosis
[133]. Another miRNA that has attracted much attention in
multiple areas of diabetes research is miR-126. Besides play-
ing a role as both mediator and marker of PDR, this miRNA
is also a biomarker of the risk of developing type 2 diabetes
[134, 135] and has been implicated in the pathogenesis of
CVD [136]. These overlaps may be advantageous as therapies
targeting single miRNAs may have beneficial effects on other
vascular beds.
In other fields, such as oncology, research on miRNAs
has already moved from gaining a better knowledge of
miRNA involvement in pathogenic mechanisms to the use
of miRNAs as targets for intervention. Gene therapy
designed to modulate miRNA expression can be applied to
either increase or decrease miRNA levels in order to obtain
desirable clinical outcomes. However, delivery to relevant tis-
sues/organs is still a major issue. Chemically modified oligo-
nucleotides, sponges, MV, viruses, and gold nanoparticles
have been tested for both effectiveness and specificity of
delivery; however, many problems still need to be addressed.
Besides delivery, treatments targeting single miRNAs can
affect many genes, as a single miRNA controls the expression
14 International Journal of Endocrinology
of multiple mRNAs, possibly causing undesired off-target
effects, and this is an important pitfall of potential new ther-
apies manipulating miRNAs.
Available data on circulating miRNAs in DMC are still
scarce, but they are likely to increase in the near future as
the number of studies assessing miRNAs as biomarkers is
growing exponentially. However, there are several limitations
in this area of research. First, reproducibility of results in
other series of patients and using different methodologies is
very poor and this underscores the importance of a coordi-
nate effort to standardize both collection and analyses of bio-
logical samples for miRNA biomarker discovery and to use
appropriate and homogenous endogenous controls. Second,
circulating miRNAs derived from damaged/necrotic cells
are a possible confounder and measurement of miRNAs
enclosed in exosomes/MV may be a preferable option. How-
ever, the procedure of exosome/vesicle isolation is both time-
consuming and expensive, making miRNAs less attractive as
biomarkers. Third, despite the growing number of studies
measuring miRNAs in body fluids, there is relatively little
knowledge on how environmental variables, including drug
therapies, affect circulating miRNA levels in normal subjects,
and this can significantly hamper our understanding of the
significance of miRNA changes in pathological conditions.
Therefore, studies covering this gap in knowledge are
desperately needed. Fourth, prospective studies in longitudi-
nal cohorts are required to evaluate whether potential novel
biomarkers of DMC have a predictive value, and their addi-
tion to currently available clinical markers and scores
improves identification of subgroup of patients at high risk
of DMC development/progression.
Most of the research on miRNA biomarkers in DMC has
been hypothesis driven and non-hypothesis-driven research
is still in its infancy in the field of diabetes. However, both
improved availability of biobanks that store samples from
clinical cohorts, and increasing experience with the use of
both omic technologies and biostatistics is likely to change
this scenario in the next future. “Molecular signatures,”
obtained using an open omic approach, are likely to outper-
form research based on individual biomarkers as single bio-
markers can hardly reflect the biological complexity of the
underlying microvascular injury.
7. Conclusions
Lately, our understanding of the importance of miRNAs in
the pathogenesis of DMC has grown substantially, and inter-
vention studies in experimental animals indicate that treat-
ments targeting miRNAs can be beneficial. Moreover, there
is increasing evidence for a potential role of miRNAs as
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clinical biomarkers of DMC. Discovery of new set of miRNA
biomarkers might help to guide diagnostic and therapeu-
tic decisions and to facilitate the implementation of per-
sonalized medicine into the clinical setting. However, novel
miRNA biomarkers must be rigorously validated in ade-
quately powered, prospective, independent clinical studies
prior to implementation in clinical practice.
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